Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

New animal model may help study immune responses to H. pylori infection

Researchers at the Virginia Bioinformatics Institute at Virginia Tech have developed a new large animal model to study how the immune system interacts with the stomach bacterium Helicobacter pylori, the leading cause of peptic ulcer disease.

26 Sep 2013

Spanish scientists discover melatonin consumption helps control weight gain

Melatonin is a natural hormone segregated by the body and melatonin levels generally increase in the dark at night. It is also found in fruit and vegetables like mustard, Goji berries, almonds, sunflower seeds, cardamom, fennel, coriander and cherries.

26 Sep 2013

Study on tempol impacted gut bacteria may lead to new treatments for obesity

A drug that appears to target specific intestinal bacteria in the guts of mice may create a chain reaction that could eventually lead to new treatments for obesity and diabetes in humans, according to a team of researchers.

25 Sep 2013

Use of insulin pump with sensor reduces rate of severe hypoglycemia

Use of an insulin pump with a sensor that suspends insulin delivery when blood glucose falls below a set threshold reduced the rate of severe and moderate hypoglycemia among patients with type 1 diabetes and impaired awareness of hypoglycemia, according to a study in the September 25 issue of JAMA.

25 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

A drug formerly used to treat the skin disorder psoriasis has shown encouraging results in a phase 2 trial to assess its effectiveness in treating type 1 diabetes, according to new research published in The Lancet Diabetes & Endocrinology.

24 Sep 2013

Understanding genetic, physiological basis for metabolic diseases related to circadian function

A new study by a team of University of Notre Dame researchers, which appears in the Sept. 2 edition of the journal PLoS ONE, is a significant step in understanding the molecular genetic and physiological basis for a spectrum of metabolic diseases related to circadian function.

24 Sep 2013

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath, Inc., the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain and diabetic neuropathy.

23 Sep 2013

Researchers report encouraging results from T1DAL study on type 1 diabetes

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby MD, PhD from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.

23 Sep 2013

Study suggests new way to prevent weight gain and obesity

The same message to everyone does not work if the goal is to prevent overweight and obesity in the population. It is also important to reach groups normally considered as being at low risk for gaining in weight. This is what Kristina Lindvall shows in her doctoral thesis at Ume- University, Sweden. Participants in the study come from V-sterbotten County in northern Sweden and from New York State in the US.

21 Sep 2013

DiaRem score predicts diabetes remission after gastric bypass

A new scoring system offers a “scientifically valid” way of predicting the 5-year likelihood for diabetes remission in patients undergoing gastric bypass surgery, say the researchers who developed the score.

20 Sep 2013

New islet transplantation improves results for patients with type 1 diabetes

The latest approach to islet transplantation, in which clusters of insulin-producing cells known as islets are transplanted from a donor pancreas into another person's liver, has produced substantially improved results for patients with type 1 diabetes, and may offer a more durable alternative to a whole pancreas transplant.

20 Sep 2013

SHBG protein indicates risk of type 2 diabetes and metabolic syndrome years in advance

Over the last decade researchers have amassed increasing evidence that relatively low levels of a protein called sex hormone binding globulin (SHBG) can indicate an elevated risk of type 2 diabetes and metabolic syndrome years in advance.

19 Sep 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

Coeliac disease on rise in Scots children

More children than ever before are living with a debilitating digestive disease, research has shown.

18 Sep 2013

Researchers identify new link between meal times and daily changes in immune system

A new link between meal times and daily changes in the immune system has been identified by UC San Francisco researchers, and has led them to question assumptions about the roles of specific immune cells in infection and allergy.

17 Sep 2013

Vanderbilt examines ability of drug abatacept to prevent type 1 diabetes

Vanderbilt's Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

17 Sep 2013

Researchers identify biomarker that can predict diabetes risk

Researchers at the Vanderbilt Heart and Vascular Institute and Massachusetts General Hospital have identified a biomarker that can predict diabetes risk up to 10 years before onset of the disease.

17 Sep 2013

Neostem Licenses UCSF Patents Covering Methods For "Tregs"

...

16 Sep 2013

Drug used in patients for cancer treatment has beneficial effects on diabetes

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular pathway - a series of interaction among proteins - involved in the development of diabetes. Furthermore, they have found that a drug already approved for use in humans can regulate the pathway.

16 Sep 2013